# Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment

> **NCT07160686** · PHASE3 · NOT_YET_RECRUITING · sponsor: **University of Birmingham** · enrollment: 1456 (estimated)

## Conditions studied

- Thromboprophylaxis

## Interventions

- **DRUG:** Apixaban
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07160686
- **Lead sponsor:** University of Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-02
- **Primary completion:** 2029-09-30
- **Final completion:** 2030-03-30
- **Target enrollment:** 1456 (ESTIMATED)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07160686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07160686, "Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07160686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*